StreetInsider.com News Articles

Prime Medicine gets New Zealand clearance for Wilson disease gene therapy

Thu, 18 Jun 2026 08:03:44 -0400

Prime Medicine, Inc. (Nasdaq: PRME) announced that New Zealand's Medicines and Medical Devices Safety Authority (Medsafe) has cleared the company's Clinical Trial Application for PM577a, an investigational Prime Editing therapy targeting Wilson Disease (WD).

According to the company, the clearance marks the first clinical authorization for an in vivo Prime Editing therapy from Prime Medicine. The company said it expects to initiate a Phase 1/2 clinical trial in the second half of 2026, with initial clinical data anticipated in 2027.

PM577a targets the H1069Q mutation in the ATP7B gene, which the company states accounts for approximately 30–50% of WD-associated variants in the

Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease

Thu, 18 Jun 2026 08:00:00 -0400

-- First clinical authorization for an in vivo Prime Editing therapy from Prime Medicine --

-- PM577a targets the H1069Q mutation in the ATP7B gene, the most prevalent WD-causing allele in North America and Europe --

-- Initiation of Phase 1/2 clinical trial expected in second half of 2026; initial clinical data expected in 2027 --

-- Shared LNP delivery platform may enable rapid expansion into additional WD pathogenic variant populations; most advanced follow-on candidate targets the R778L mutation frequently found in East Asian populations --

CAMBRIDGE, Mass., June 18,

Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease

Thu, 18 Jun 2026 08:00:00 -0400

-- First clinical authorization for an in vivo Prime Editing therapy from Prime Medicine --

-- PM577a targets the H1069Q mutation in the ATP7B gene, the most prevalent WD-causing allele in North America and Europe --

-- Initiation of Phase 1/2 clinical trial expected in second half of 2026; initial clinical data expected in 2027 --

CAMBRIDGE, Mass., June 18,

Prime Drink Group raises up to $2.2 million in private placement

Fri, 12 Jun 2026 18:30:14 -0400

Prime Drink Group Corp. (CSE: PRME) announced a non-brokered private placement offering to raise between $1.2 million and $2.2 million through the sale of units priced at $10,000 each.

Each unit consists of 200,000 common shares at a deemed price of $0.05 per share and 200,000 transferable share purchase warrants. The warrants allow holders to purchase common shares at $0.10 per share for one year from the issuance date.

The offering will result in the issuance of 24 million to 44 million common shares and an equal number of warrants, depending on subscription levels. The securities are subject to a four-month and

Prime Drink Group raises up to $2.2 million in private placement

Fri, 12 Jun 2026 18:30:14 -0400

Prime Drink Group Corp. (CSE: PRME) announced a non-brokered private placement offering to raise between $1.2 million and $2.2 million through the sale of units priced at $10,000 each.

The offering will result in the issuance of 24 million to 44 million common shares and an equal number of warrants, depending on subscription levels. The securities are subject to a four-month and

Prime Drink Group Announces Private Placement and Agreed Resolution with Creditors

Fri, 12 Jun 2026 18:30:00 -0400

MONTREAL, June 12, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that it is proceeding with a non-brokered private placement offering of units of the Company (the “Units”) to raise minimum gross proceeds of $1,200,000 and maximum gross proceeds of $2,200,000 (the “Unit Offering”).

Each Unit will be offered at a price of $10,000 per Unit and is comprised of 200,000 common shares in the capital of the Company (the “Common Shares”) and 200,000 transferable share purchase warrants (the “Warrants”), resulting in the aggregate issuance of a minimum

Prime Drink Group Announces Private Placement and Agreed Resolution with Creditors

Fri, 12 Jun 2026 18:30:00 -0400

Prime Drink Group Announces Private Placement and Agreed Resolution with Creditors

Fri, 12 Jun 2026 18:30:00 -0400

Prime Drink Group Announces Private Placement and Agreed Resolution with Creditors

Fri, 12 Jun 2026 18:30:00 -0400

Form 4 Prime Medicine, Inc. For: Jun 05 Filed by: Schenkein David P

Mon, 08 Jun 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260608/26617659.html

Form 4 Prime Medicine, Inc. For: Jun 05 Filed by: Schenkein David P

Mon, 08 Jun 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260608/26617659.html

Form 4 Prime Medicine, Inc. For: Jun 05 Filed by: Marrazzo Jeffrey D

Mon, 08 Jun 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260608/26617643.html

Form 4 Prime Medicine, Inc. For: Jun 05 Filed by: Marrazzo Jeffrey D

Mon, 08 Jun 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260608/26617643.html

Form 4 Prime Medicine, Inc. For: Jun 05 Filed by: NELSEN ROBERT

Mon, 08 Jun 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260608/26617616.html

Form 4 Prime Medicine, Inc. For: Jun 05 Filed by: NELSEN ROBERT

Mon, 08 Jun 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260608/26617616.html

Form 4 Prime Medicine, Inc. For: Jun 05 Filed by: Kelly Michael Aaron

Mon, 08 Jun 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260608/26617599.html

Form 4 Prime Medicine, Inc. For: Jun 05 Filed by: Kelly Michael Aaron

Mon, 08 Jun 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260608/26617599.html

Form 4 Prime Medicine, Inc. For: Jun 05 Filed by: Foster-Cheek Kaye I

Mon, 08 Jun 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260608/26617575.html

Form 4 Prime Medicine, Inc. For: Jun 05 Filed by: Foster-Cheek Kaye I

Mon, 08 Jun 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260608/26617575.html

Form 4 Prime Medicine, Inc. For: Jun 05 Filed by: Chung Wendy

Mon, 08 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260608/26617507.html

Form 4 Prime Medicine, Inc. For: Jun 05 Filed by: Chung Wendy

Mon, 08 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260608/26617507.html

Form 4 Prime Medicine, Inc. For: Jun 05 Filed by: Cahill Thomas

Mon, 08 Jun 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260608/26617474.html

Form 4 Prime Medicine, Inc. For: Jun 05 Filed by: Cahill Thomas

Mon, 08 Jun 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260608/26617474.html

Form 8-K Prime Medicine, Inc. For: Jun 05

Mon, 08 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260608/26617410.html

Form 8-K Prime Medicine, Inc. For: Jun 05

Mon, 08 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260608/26617410.html